Monday August 26, 2019 Announcement Offers Hope For Cannabis Community
In a low-key public announcement today the DEA issued a statement saying that it will soon be issuing guidelines for handling applications for growing cannabis for scientific and medical research. Experts believe this move will lead to downgrading the classification of marijuana on the controlled substances list, in addition to opening the doors to more clinical trials for cannabis derived drugs.
The move also ends the monopoly on supply to researchers, opening more avenues for acquiring cannabis for testing and research. Prior to today’s announcement only one supplier was approved by the National Institute on Drug Abuse, a University of Mississippi facility according to ThinkProgress.org.
Sponsored Link: Get High Quality Nutritional Supplements & Vitamins
After years of complaints by researchers, and a lawsuit pending to come to court in the next few coming days, the DEA has decided to move in a more friendlier direction in regards to cannabis research. The announcement also bolsters hopes to cannabis advocates looking for decriminalization and/or legalization of marijuana as well.
Stay tuned to Disciple 420 for more on this developing story. Thanks for reading and be sure to check out our other latest Disciple 420 posts.
- DEA Statement on “Bulk Manufacturer of Controlled Substances Applications: Bulk Manufacturers of Marihuana” – https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-18456.pdf
- ThinkProgress.org Article – “The DEA just made a huge change to how the government treats medical marijuana” – https://thinkprogress.org/dea-concedes-that-marijuana-research-monopoly-must-end-opening-door-to-sweeping-change-2d60015acd1d/